Share Name Share Symbol Market Type Share ISIN Share Description
International Biotechnology Trust Plc LSE:IBT London Ordinary Share GB0004559349 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 580.00p 578.00p 580.00p 580.00p 580.00p 580.00p 393 08:12:56
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.0 -2.5 -6.9 - 222

International Biotechnol... Share Discussion Threads

Showing 476 to 500 of 500 messages
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
According to the most recent monthly factsheet, the NAV as at financial year end on 31/8/2019 was £239m (622p per share). HTTPS:// Current dividend policy is to pay out an amount eqivalent to 4% of yr end NAV in two tranches. NAV as at 31/8/2018 was 699p which equated to a dividend of 28.0p in the current FY (2 x 14.0p payments) If NAV as at 31/8/2019 was 622p, this would appear to equate to a dividend of 24.75-25.0p over the next 12 months, which would represent a reduction of c.11-12%.
You can meet the managers of International Biotechnology Trust at the Mello Trust and Funds Show. We all have discounted tickets available from ShareSoc, full members get an originally £49 ticket for the reduced price of £24.50 - hTTps://
QuoteData- Beating the odds view report Strategic positioning in mid-2018 helped International Biotechnology Trust (IBT) beat its benchmark over the past six months and close its discount to net asset value (NAV). This continued its outperformance of the US Nasdaq Biotechnology Index (NBI) over three and five years. Active management of the portfolio and an increased focus on larger mid-caps played out well in terms of IBT’s performance versus its peers. IBT’s manager is maintaining its established policy of active risk mitigation, designed to avoid exposure to binary events that can cause large swings in the share price (typically the results of the Phase III trials that provide the final confirmation of safety and efficacy before the FDA approves a treatment for marketing). This should be seen as another attraction to investors in the trust. IBT’s shares have recently moved to trade at a premium to NAV and it has been issuing stock, expanding the fund. SECTOR: SECTOR SPECIALIST - BIOTECHNOLOGY AND HEALTHCARE TICKER: IBT LN BASE CURRENCY: GBP (PENCE) PRICE: 634.00P NAV: 636.40P PREMIUM/(DISCOUNT): (0.4%) YIELD: 4.4% spacer spacer spacer ACCESS TO THE FAST-GROWING BIOTECH SECTOR charticon spacer spacer spacer spacer IBT is the longest-established of the London-listed funds specialising in the biotech/healthcare sector. It aims to achieve long-term capital growth by investing in biotechnology and other life sciences companies, and offers investors the highest yield in the sector while keeping its day-to-day running costs low. The portfolio is invested primarily in quoted companies, but IBT also has some exposure to unquoted compani
Here's IBTs presentation at Mello London 2018, given by Carl Harald Janson, Lead Investment Manager. A comprehensive overview of the IT, which gives insight to the biotech sector, the growth drivers, the investment process at IBT, risk and how handled. Https://
Just to let you all know that IBT will be exhibiting and presenting at our very big investor event in Chiswick W4 next month on 26th and 27th November. MelloLondon is a two day event and starts on Monday 26th November. You can find out more here... Http:// There will be 60 quality companies exhibiting and presenting plus some very well known investors, entrepreneurs, fund managers and market commentators providing excellent keynote talks on a range of investment subjects. A number of investment workshops will be available each day and a ShareSoc MasterClass on the final day.
IBT factsheet (Sept 2018) - HTTPS:// OUTLOOK Based on strong Q2 earnings, the market has shown increased interest in the larger biotechnology companies. Uncertainty created by looming US mid-term elections in November may generate continued favour towards larger companies in the sector. Our view is that the Republican Party will remain industry friendly and expect free market forces to continue unchanged, but the outcome of the elections is still uncertain. Whatever the outcome, we expect the innovative mid and small caps to thrive. Innovation is stronger than ever, demonstrated in areas like oncology, where many new drugs and drug classes meet a great medical need. However, it is our view that the current valuation of the healthcare sector remains low.
Video of the IBT presentation at ShareSoc April 18, by Lead Investment Manager Dr Carl Harald Janson. Https:// International Biotechnology Trust offers investors access to the fast growing biotechnology sector through an actively managed, diversified fund. Its award winning fund managers at SV Health Investors are scientifically and medically trained with over 60 years of experience in this specialist sector between them. As well as investing in a wide ranging portfolio of global quoted biotechnology stocks, we include a small proportion of otherwise inaccessible carefully selected unquoted investments which have the potential to deliver additional returns over the long term. Excellent management teams, unique innovative products and strong potential for outperformance are the key criteria for inclusion in our diversified portfolio of assets. International Biotechnology Trust introduction video – 00:22 Dr Carl Harald Janson, Lead Investment Manager introduction – 03:07 Performance 1, 3 & 5 years – 3:47 Dividend – 05:06 Share price/discount – 05:42 Dividend sustainability – 06:34 Biotech is a high growth sector – 07:25 Favourable regulatory environment – 10:45 Worldwide pharma sales – 11:15 M&A – 11:37 Risks – 13:15 The US market – 14:11 Sector valuation – 16:13 IBT investment process – 17:04 Risk mitigation – 17:54 Portfolio breakdown – 19:42 Oncology treatment options – 21:54 Top 10 holdings – 23:14 Unqouted portfolio – 24:00 Awards & Summary -25:58 Q&A -25:19
Portfolio Update - HTTPS:// The Board of International Biotechnology Trust plc (the Company) notes the following unquoted portfolio event. The Company has received quarterly investor reporting in relation to its investment in the unlisted venture capital fund, SV Fund VI. SV Fund VI's latest quarterly investor report values the Company's investment at $25.0m (£19.6m), an uplift of $3.4m (£2.7m) on the valuation of $21.6m (£16.9m) which was included in the Company's Net Asset Value (NAV) calculation for 13 August 2018. In line with the Company's accounting policy, valuation movements following receipt of quarterly investor reports are reflected in the next reported NAV. Therefore, the increase in NAV to be reported today, as at 14 August 2018, will be £2.7m or 7.2 pence per share.
Thanks Speedsgh.
the oak tree
Think this may have had a helping hand from the latest article in John Baron's Investment Trust Portfolio column in Investors Chronicle... Biotechnology: best yet to come? - HTTPS://
Looking like this is breaking out. About time!
mad foetus
The International Biotechnology presentation and stockopedia report from our seminar in London on the 18th April can be found in our members area here: hTTps://
Half-year Report - HTTPS:// Summary In the shorter term, over the six months to 28 February 2018, the NAV per Ordinary share of the Company fell from 672.9p to 603.2p. The decrease in NAV per share was driven by a dividend payment of 13.5p per share, that was announced in December 2017 and paid on 31 January 2018, and a currency loss of £16.9m, equivalent to 45.0 pence per share. The NAV per share returned -6.5% including the dividend. Over the same period, the Ordinary share price of the Company decreased by 4.0%. This compares to a fall in the NBI of 8.8% and a fall in the FTSE All-Share Index of 0.9%. All figures are on a total return basis and are sterling-adjusted. Performance has been held back by the impact of the GBP strengthening 6.4% vs. the USD over the period. With the prospect of increased growth and innovation, I believe the biotechnology sector remains an attractive sector for our investors, capable of delivering enhanced Shareholder returns. The outlook is more fully explained in the Investment Manager's Review... Dividends, buybacks and discount I am pleased to report a dividend payment was made to our Shareholders on 31 January 2018 at a rate of 13.5p per share, a 17.4% increase on last year's dividend. The second tranche of the dividend will be announced in July, and is expected to be 13.5p, with the two equal tranches equating to 4% of NAV as at 31 August 2017. Since the announcement of our policy changes and the introduction of the dividend in September 2016, no further buybacks have been required in line with our discount control policy. Indeed, the discount narrowed to 2.9% from 7.3% at the previous year end. Performance fee No performance fee has been generated by either the quoted portfolio or the unquoted portfolio in the period. The quoted portfolio has outperformed the NBI, but has not outperformed by more than the 0.5% hurdle required to give rise to a performance fee. The unquoted portfolio has returned 6.2% in the period, significantly outperforming the NBI, however the unquoted portfolio performance fee is based on net realised gains, taking into account any unrealised losses but not unrealised gains. As the gains in the period are unrealised, no performance fee is due on the unquoted portfolio. Prospects The Investment Manager has outperformed the market in varying conditions, in both rising and falling markets. Drug pricing and political concerns have prevented the sector from participating in the broader market rally which I believe gives investors an excellent opportunity to gain exposure to a sector with exciting growth prospects. It is clear that the larger names within the biotechnology sector are seeing their growth rates slow. The Investment Manager's strategy of tilting the Company away from these names and into the higher growth mid-sized companies continues. The Investment Manager believes that by investing in the next generation of businesses with newly launched drugs and innovative pipelines, we maximise potential for long-term growth and exposure to possible Merger & Acquisitions (M&A) candidates. I am optimistic that exposure to the sector through a fund managed by medical experts can identify such names and generate returns for our Shareholders.
International Biotechnology Trust present at our upcoming growth company seminar on the 18th April which may be of interest to potential investors and current shareholders: hTTps://
oops- See the last part. hTTp://
Bought in here on Friday (along with BIOG) so keen on others views. Its had a good run though and little if any discount. Its part of a balanced portfolio but feel its a merited position due to this sector perhaps going through what technology has done this last 20 years. Bio science will have its iPhone / google maps moment as some point in the next 10-20 years I reckon. IMHO
the oak tree
IBT won the best specialist investment trust at the Citywire awards this week. All positive publicity.
mad foetus
I'm buying at this level for the long term. GLA.
mad foetus
The pick up in biotech shares came at a good time because of next years dividend is linked to the end august 2017 NAV I believe. Also nice to see the price increase of course.
vertex up sharply last night in US 25% + in aftermarket - is a 5% plus position in IBT Why I hold trusts like this : )
near 10% jump in NAV from last week: Date NAV Pence ------------- ------------ ------- Thursday 22 Jun Ex Income 681.27 Date NAV Pence --------------- ------------ ------- Friday 16 Jun Ex Income 620.86
Sharp rises these last few days; any fundamental reason?
Discount has closed slightly. Would be tempted if it widens but not sure that is the way it's going.
its the oxman
Happy with the update this morning and still well discounted to NAV. With a chunky dividend yield now, I think I will be adding to my position here. TT
Discount now 11% but hitting new highs.Slow and steady I suppose,that's investment trusts for you.
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191018 08:26:01